Haemonetics Acquires Vivasure Medical Limited

Rhea-AI Summary

Haemonetics (NYSE: HAE) acquired Vivasure Medical Limited, a Galway-based developer of the PerQseal Elite percutaneous large-bore vessel closure system.

The deal includes an upfront cash payment of €100 million (approximately €52 million net of prior investments/loans and adjustments) and up to €85 million of contingent consideration tied to sales growth and milestones. Haemonetics financed the acquisition with available cash on hand.

Vivasure submitted a PMA application to the U.S. FDA in 2025 and holds CE Mark approval in Europe for arterial and venous indications. The ELITE study reported 0% major complications at 30 days and immediate median time to hemostasis.

Positive

• Upfront consideration of €100M increases Haemonetics' portfolio in large-bore closure
• Up to €85M contingent earnout aligns payment with Vivasure sales/milestones
• CE Mark for arterial and venous indications supports European commercialization
• Vivasure submitted a 2025 FDA PMA, creating a U.S. regulatory pathway
• ELITE study: 0% major complications at 30 days indicating strong short-term safety

Negative

• Upfront payment net of prior investments reduced to approximately €52M
• Contingent consideration up to €85M depends on future sales performance
• PerQseal and PerQseal Elite are not available for sale in the U.S. pending FDA outcome

Key Figures

Arteriotomy size up to 26 F Large-bore arteriotomies and venotomies for PerQseal Elite

Major complications 0% ELITE arterial study, thirty-day follow-up

Upfront payment €100 million Cash consideration for Vivasure acquisition

Net upfront outlay approximately €52 million Net of prior investments and loans from Haemonetics

Contingent consideration up to €85 million Milestone- and sales-based earn-out for Vivasure

PMA submission year 2025 Premarket Approval application for PerQseal Elite to U.S. FDA

CE Mark year 2025 CE Mark approval for arterial and venous indications

Market cap $3,885,202,776 Pre-announcement market capitalization for HAE

Market Reality Check

$82.03 Last Close

Volume Volume 805,837 is 1.19x the 20-day average 674,788, indicating slightly elevated activity before this announcement. normal

Technical Price 84.04 is trading above the 200-day MA at 65.48 and within 3.76% of the 52-week high 87.32.

Peers on Argus

HAE was up 1.25% pre-announcement. Peers showed mixed but mostly positive moves: ATEC +1.93%, ITGR +3.27%, LIVN +1.2%, PRCT +2.22%, while INSP declined 3.05%. This points to a stock-specific story rather than a uniform sector rotation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
2026-01-02	Conference appearance	Neutral	-0.2%	Announcement of JPMorgan healthcare conference presentation and webcast access.
2025-11-06	Earnings release posted	Neutral	+32.3%	Second quarter fiscal 2026 results and materials posted on IR site.
2025-10-09	Earnings date set	Neutral	-2.6%	Scheduling of Q2 fiscal 2026 results release and conference call.
2025-08-07	Earnings release posted	Neutral	-26.6%	First quarter fiscal 2026 results and webcast details made available.
2025-07-09	Earnings date set	Neutral	+0.8%	Announcement of date and logistics for Q1 fiscal 2026 results.

Pattern Detected

Recent scheduled events (earnings releases and conference appearances) have triggered large but mixed price reactions, including one strong gain and one sharp selloff around earnings postings.

Recent Company History

Over the last six months, Haemonetics’ news flow has focused on earnings communications and investor outreach. Multiple items in July–August 2025 and November 2025 set or reported fiscal 2026 results, with one earnings release linked to a +32.31% move and another to a -26.58% move. A January 2026 conference presentation notice had a minimal -0.21% reaction. Against this backdrop, the Vivasure acquisition adds a distinct strategic transaction to an otherwise cadence-driven news pattern.

Market Pulse Summary

This announcement details Haemonetics’ acquisition of Vivasure, adding the PerQseal Elite large-bore closure system, which showed 0% major complications at thirty days and has both U.S. PMA submission and European CE Mark. Pre-announcement, HAE traded near its 52-week high and above its 65.48 200-day MA. Investors may watch integration progress, regulatory milestones for PerQseal Elite, and how the new platform contributes to future earnings updates.

Key Terms

percutaneous medical

"pioneering next-generation technology for percutaneous vessel closure."

Percutaneous describes medical procedures or delivery methods that reach internal organs or tissues by passing through the skin — for example with needles, catheters or small tubes — instead of opening the body with large incisions. For investors it matters because percutaneous approaches are generally less invasive, often mean lower hospital time, quicker recovery and smaller device footprints, which can broaden market adoption and affect regulatory and reimbursement outlooks.

arteriotomies medical

"patch to seal large-bore (up to 26 F) arteriotomies and venotomies"

An arteriotomy is a surgical cut made into an artery to gain access for procedures like placing catheters, stents, or performing repairs. For investors, the prevalence and safety of arteriotomies affect demand for closure devices, surgical tools and consumables because these cuts carry bleeding and infection risks and require reliable ways to seal the artery—like making a doorway in a water pipe that must be securely closed afterward.

venotomies medical

"patch to seal large-bore (up to 26 F) arteriotomies and venotomies"

A venotomy is a medical procedure that involves making a small cut into a vein to gain direct access for treatment, such as inserting a catheter, removing a clot, or taking a tissue sample. It matters to investors because the need for venotomies drives demand for surgical tools, catheters and clot-removal devices and can affect hospital procedure volumes, device company revenues, and regulatory scrutiny tied to patient safety and outcomes—similar to how a repair opening enables a mechanic to fix a car and shapes sales of shop tools.

premarket approval regulatory

"submitted a Premarket Approval application to the U.S. FDA"

Premarket approval is the formal regulatory clearance required before certain medical devices can be sold, based on detailed evidence that the product is safe and effective. For investors, it’s a major milestone because receiving approval typically clears the way for commercial sales and reduces regulatory uncertainty, while failure or delays can block revenue and raise the risk profile; think of it like a safety certificate needed before a new car model can be sold.

ce mark regulatory

"received CE Mark approval in Europe for both arterial and venous"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

hemostasis medical

"with 0% major complications at thirty-day follow-up, and immediate median time to hemostasis"

Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.

iso 13485 technical

"operates a fully integrated R&D and ISO 13485 certified manufacturing facility."

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

AI-generated analysis. Not financial advice.

BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.

Vivasure's PerQseal^® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite arterial closure system and received CE Mark approval in Europe for both arterial and venous indications. Results from the prospective, single-arm, multi-center ELITE arterial study demonstrated ease of use with no need for pre-close, with 0% major complications at thirty-day follow-up, and immediate median time to hemostasis¹.

The acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments, and up to an additional €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. Haemonetics financed this transaction through available cash on hand.

"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures," said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics. "With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals."

"We're extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure's mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide," said Andrew Glass, Chief Executive Officer of Vivasure Medical Limited.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

About Vivasure Medical Limited

Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility.

PerQseal and PerQseal Elite are not available for sale in the United States. For more information, please visit www.vivasuremedical.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for the operation of Haemonetics, (ii) the anticipated benefits to Haemonetics arising from the completion of the acquisition, (iii) the impact of the acquisition on Haemonetics' business strategy and future business and operational performance, and (iv) the assumptions underlying or relating to any such statement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the acquisition or the acquisition having an unanticipated impact; Haemonetics' ability to predict accurately the demand for products and products under development by it or Vivasure Medical Limited and to develop strategies to successfully address relevant markets; actual and anticipated achievement of the future sales growth and other milestones on which contingent consideration is based; the impact of competitive products and pricing; regulatory uncertainties, including in the receipt or timing of regulatory approvals; technical innovations that could render products marketed or under development by Haemonetics or Vivasure Medical Limited obsolete and risks related to the use and protection of intellectual property. These and other factors are identified and described in more detail in Haemonetics' filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.

¹ In per-protocol population; Major Vascular Complications per VARC-3 definition

Investor Contacts:
Olga Guyette, VP-Investor Relations & Treasury	David Trenk, Manager-Investor Relations
(781) 356-9763	(203) 733-4987
olga.guyette@haemonetics.com	david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Senior Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-acquires-vivasure-medical-limited-302657255.html

SOURCE Haemonetics Corporation

FAQ

What acquisition did Haemonetics announce on January 9, 2026 (NYSE: HAE)?

Haemonetics announced the acquisition of Vivasure Medical Limited, maker of the PerQseal Elite large-bore closure system.

How much did Haemonetics pay to acquire Vivasure (HAE)?

The transaction includes an upfront cash payment of €100 million (≈€52M net of prior investments/loans) plus up to €85 million in contingent consideration.

Does Vivasure have regulatory approvals for PerQseal Elite?

PerQseal Elite holds a CE Mark in Europe for arterial and venous indications and a PMA application was submitted to the U.S. FDA in 2025.

What clinical evidence supports PerQseal Elite reported in the announcement?

The prospective ELITE arterial study reported 0% major complications at 30 days and immediate median time to hemostasis.

How was the Vivasure acquisition financed by Haemonetics (HAE)?

Haemonetics financed the transaction through available cash on hand.